Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes

Abstract Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis of data from the EMPA-REG study, elevations in haematocrit were shown...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jens Aberle, Markus Menzen, Sebastian M. Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F. Scheerer, John Xu, Weifeng Tang, Andreas L. Birkenfeld
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4ef2b8e15fa34ef09f3620b326bc5c84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ef2b8e15fa34ef09f3620b326bc5c84
record_format	dspace
spelling	oai:doaj.org-article:4ef2b8e15fa34ef09f3620b326bc5c842021-12-02T15:12:41ZDapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes10.1038/s41598-020-78734-z2045-2322https://doaj.org/article/4ef2b8e15fa34ef09f3620b326bc5c842020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78734-zhttps://doaj.org/toc/2045-2322Abstract Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis of data from the EMPA-REG study, elevations in haematocrit were shown to be strongly associated with beneficial CV effects. As insulin treatment has been shown to be antinatriuretic, with an associated increase in extracellular fluid volume, it is important to confirm whether haematocrit increase is maintained with concomitant insulin therapy. Here, we investigate the effect of the SGLT2 inhibitor dapagliflozin on haematocrit, red blood cell (RBC) counts and reticulocyte levels in high-risk patients with T2DM receiving insulin. A 24-week, double-blinded, randomised, placebo-controlled trial (ClinicalTrials.gov: NCT00673231) was reported previously with extension periods of 24 and 56 weeks (total of 104 weeks). Patients receiving insulin were randomised 1:1:1:1 to placebo or dapagliflozin at 2.5, 5 or 10 mg. Haematocrit, RBC and reticulocyte measurements were conducted during this study, and a longitudinal repeated-measures analysis was performed here to examine change from baseline during treatment. Dapagliflozin treatment in combination with insulin resulted in a dose-dependent increase in haematocrit levels and RBCs over a 104 week period. There was a short-term increase in reticulocyte levels at the start of treatment, which dropped to below baseline after 8 weeks. SGLT2 inhibition with dapagliflozin leads to a sustained increase in haematocrit in patients receiving chronic insulin treatment.Jens AberleMarkus MenzenSebastian M. SchmidChristoph TerkampElmar JaeckelKatja RohwedderMarkus F. ScheererJohn XuWeifeng TangAndreas L. BirkenfeldNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jens Aberle Markus Menzen Sebastian M. Schmid Christoph Terkamp Elmar Jaeckel Katja Rohwedder Markus F. Scheerer John Xu Weifeng Tang Andreas L. Birkenfeld Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
description	Abstract Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis of data from the EMPA-REG study, elevations in haematocrit were shown to be strongly associated with beneficial CV effects. As insulin treatment has been shown to be antinatriuretic, with an associated increase in extracellular fluid volume, it is important to confirm whether haematocrit increase is maintained with concomitant insulin therapy. Here, we investigate the effect of the SGLT2 inhibitor dapagliflozin on haematocrit, red blood cell (RBC) counts and reticulocyte levels in high-risk patients with T2DM receiving insulin. A 24-week, double-blinded, randomised, placebo-controlled trial (ClinicalTrials.gov: NCT00673231) was reported previously with extension periods of 24 and 56 weeks (total of 104 weeks). Patients receiving insulin were randomised 1:1:1:1 to placebo or dapagliflozin at 2.5, 5 or 10 mg. Haematocrit, RBC and reticulocyte measurements were conducted during this study, and a longitudinal repeated-measures analysis was performed here to examine change from baseline during treatment. Dapagliflozin treatment in combination with insulin resulted in a dose-dependent increase in haematocrit levels and RBCs over a 104 week period. There was a short-term increase in reticulocyte levels at the start of treatment, which dropped to below baseline after 8 weeks. SGLT2 inhibition with dapagliflozin leads to a sustained increase in haematocrit in patients receiving chronic insulin treatment.
format	article
author	Jens Aberle Markus Menzen Sebastian M. Schmid Christoph Terkamp Elmar Jaeckel Katja Rohwedder Markus F. Scheerer John Xu Weifeng Tang Andreas L. Birkenfeld
author_facet	Jens Aberle Markus Menzen Sebastian M. Schmid Christoph Terkamp Elmar Jaeckel Katja Rohwedder Markus F. Scheerer John Xu Weifeng Tang Andreas L. Birkenfeld
author_sort	Jens Aberle
title	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
title_short	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
title_full	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
title_fullStr	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
title_full_unstemmed	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
title_sort	dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/4ef2b8e15fa34ef09f3620b326bc5c84
work_keys_str_mv	AT jensaberle dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT markusmenzen dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT sebastianmschmid dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT christophterkamp dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT elmarjaeckel dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT katjarohwedder dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT markusfscheerer dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT johnxu dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT weifengtang dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes AT andreaslbirkenfeld dapagliflozineffectsonhaematocritredbloodcellcountandreticulocytesininsulintreatedpatientswithtype2diabetes
_version_	1718387626828890112

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes

Ejemplares similares